DanaherDHR
DHR
About: In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
Employees: 63,000
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 13 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
139% more first-time investments, than exits
New positions opened: 198 | Existing positions closed: 83
55% more call options, than puts
Call options by funds: $2.23B | Put options by funds: $1.43B
31% more funds holding in top 10
Funds holding in top 10: 74 [Q2] → 97 (+23) [Q3]
4% more funds holding
Funds holding: 2,139 [Q2] → 2,228 (+89) [Q3]
5% more capital invested
Capital invested by funds: $153B [Q2] → $159B (+$6.91B) [Q3]
0% less repeat investments, than reductions
Existing positions increased: 847 | Existing positions reduced: 848
3.06% less ownership
Funds ownership: 81.59% [Q2] → 78.53% (-3.06%) [Q3]
Research analyst outlook
13 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$265
11%
upside
Avg. target
$292
23%
upside
High target
$315
32%
upside
13 analyst ratings
10 positive
77%
3 neutral
23%
0 negative
0%
Citigroup Patrick Donnelly 47% 1-year accuracy 15 / 32 met price target | 20%upside $285 | Buy Maintained | 6 Jan 2025 |
Scotiabank Sung Ji Nam 60% 1-year accuracy 12 / 20 met price target | 11%upside $265 | Sector Perform Initiated | 23 Dec 2024 |
B of A Securities Derik De Bruin 68% 1-year accuracy 13 / 19 met price target | 22%upside $290 | Buy Upgraded | 13 Dec 2024 |
Wolfe Research Doug Schenkel 20% 1-year accuracy 1 / 5 met price target | 20%upside $285 | Outperform Upgraded | 31 Oct 2024 |
RBC Capital Conor McNamara 29% 1-year accuracy 11 / 38 met price target | 30%upside $311 | Outperform Maintained | 23 Oct 2024 |
Financial journalist opinion
Based on 12 articles about DHR published over the past 30 days
Positive
Seeking Alpha
4 days ago
Danaher: Transition Year Recap
Danaher faced a disappointing 2024, despite beating Q3 expectations, due to unaltered full-year guidance and a significant asset writedown. The company executed a $4.5 billion share buyback, with an additional 20 million shares authorized, reflecting confidence in long-term growth. Danaher's ROIC appears low due to heavy R&D and capex investments, but this expands its competitive moat and deters new entrants.
Positive
Seeking Alpha
4 days ago
The Near-Perfect Dividend Portfolio With 10 Sleep-Well-At-Night Gems
In a challenging market marked by uncertainty, building a resilient portfolio is key to long-term financial stability and peace of mind. Sleep-well-at-night, or SWAN, stocks are key. These reliable dividend stocks thrive despite volatility, offering steady income and solid growth in uncertain times. Building a balanced portfolio of 10 carefully selected SWAN stocks ensures consistent returns. This strategy offers peace of mind, regardless of market fluctuations.
Neutral
PRNewsWire
5 days ago
Beckman Coulter Introduces Cutting-Edge Research Use Only Assays for Neurodegenerative Disease Research
New, Fully Automated, High-Throughput RUO Assays offered on Beckman Coulter Immunoassay Analyzers BREA, Calif. , Jan. 15, 2025 /PRNewswire/ -- Beckman Coulter Diagnostics, a global leader in advanced diagnostics, today announced availability of new Research Use Only (RUO) blood-based biomarker immunoassays designed to advance neurodegenerative disease research.
Neutral
Seeking Alpha
5 days ago
Danaher Corporation (DHR) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
Danaher Corporation (NYSE:DHR ) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2024 2:15 PM ET Company Participants Rainer Blair - President and Chief Executive Officer Conference Call Participants Rachel Vatnsdal - J.P.
Neutral
PRNewsWire
6 days ago
Danaher CEO to Comment on Financial Performance
WASHINGTON , Jan. 13, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") announced that its President and Chief Executive Officer, Rainer M. Blair, will comment tomorrow on the Company's fourth quarter 2024 performance in a presentation at the J.P.
Negative
Seeking Alpha
1 week ago
Using SA's Stock Screener: Sell 6 Overvalued Blue Chips, With Stagnating Growth
Seeking Alpha's Quant Valuation and Growth Grades identify 6 blue-chip stocks with extremely high valuations matched against limited operating growth potential. Costco, Cencora, West Pharmaceutical Services, Danaher, Madison Square Garden Sports, and Estée Lauder appear to be at risk of disappointing investors in 2025. Weakening technical performance vs. the S&P 500 is part of the bearish sell/avoid equation for each since summer.
Neutral
PRNewsWire
1 week ago
Danaher Announces Investment Partnership in Innovaccer Inc.
Partnership seeks to improve patient outcomes and experience through novel digital and diagnostic solutions. Investment aligns with Danaher's mission to accelerate the transition to precision medicine with AI-enabled diagnostics.
Neutral
PRNewsWire
1 week ago
Danaher to Present at J.P. Morgan Healthcare Conference
WASHINGTON , Jan. 6, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that its President and Chief Executive Officer, Rainer M. Blair, will be presenting at the J.P.
Positive
Seeking Alpha
2 weeks ago
Danaher: A Wide-Moat Gem I Cannot Buy Enough Of
Danaher boasts a wide-moat business model with mission-critical products and recurring revenue streams, ensuring a durable competitive advantage and long-term growth potential. The company's disciplined M&A strategy and integration capabilities have driven significant value creation, supported by strong secular healthcare trends and a focus on innovation. Despite a modest 0.5% dividend yield, Danaher's 12.4% five-year CAGR and low payout ratio offer substantial growth potential for total return investors.
Positive
Zacks Investment Research
2 weeks ago
Will Danaher (DHR) Beat Estimates Again in Its Next Earnings Report?
Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Charts implemented using Lightweight Charts™